불면증 치료제 시장 : 규모, 점유율, 성장률, 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of insomnia drugs Market

The global insomnia drugs market was valued at USD 4.50 billion in 2025 and is projected to grow from USD 4.86 billion in 2026 to USD 8.90 billion by 2034, registering a CAGR of 7.86% during the forecast period. North America dominated the market with a 44.88% share in 2025, driven by a high prevalence of sleep disorders, strong healthcare infrastructure, and rapid adoption of innovative insomnia therapies.

Insomnia has become one of the most common sleep disorders worldwide, affecting millions of individuals across different age groups. Rising stress levels, anxiety, depression, changing lifestyles, excessive screen exposure, and irregular work schedules have significantly increased the number of patients seeking medical intervention for sleep-related disorders. The growing burden of chronic insomnia is encouraging pharmaceutical companies to develop safer and more effective treatment options that improve both nighttime sleep quality and daytime functioning.

The market is witnessing a notable shift toward next-generation therapies, particularly Dual Orexin Receptor Antagonists (DORAs), which offer improved efficacy and reduced next-day sedation compared to traditional hypnotic drugs. Continuous research and development activities by major pharmaceutical companies are expected to drive future market growth.

Market Trends

Rising Preference for Safer and Better-Tolerated Insomnia Therapies

One of the most significant trends in the insomnia drugs market is the growing demand for therapies that provide effective sleep benefits with fewer side effects. Patients and healthcare providers are increasingly cautious about conventional sleep medications due to concerns regarding dependency, cognitive impairment, and residual daytime drowsiness.

As a result, newer therapies such as orexin receptor antagonists are gaining popularity. These drugs are designed to promote natural sleep patterns while minimizing next-morning impairment. The increasing focus on improving both sleep quality and daytime performance is reshaping prescribing patterns globally.

Market Drivers

Increasing Prevalence of Insomnia and Sleep Disorders

The primary driver of market growth is the rapidly increasing prevalence of insomnia worldwide. Growing mental health concerns, aging populations, work-related stress, and chronic health conditions have significantly increased the number of patients experiencing sleep disturbances.

According to recent global studies, more than 850 million adults worldwide suffer from insomnia, creating substantial demand for pharmaceutical treatment options. As awareness regarding the importance of sleep health continues to rise, diagnosis rates and treatment-seeking behavior are expected to increase further, supporting long-term market expansion.

Market Restraints

Safety Concerns Associated with Long-Term Drug Use

Despite growing demand, concerns regarding long-term safety remain a major challenge for the market. Several insomnia medications are associated with dependency risks, falls, residual sedation, and cognitive impairment, particularly among elderly patients.

Healthcare providers often recommend short-term use of certain sleep medications, limiting long-term prescription growth. These concerns continue to influence prescribing decisions and slow broader adoption of some drug classes.

Market Opportunities

Growing Awareness of Sleep Health

Increasing awareness about the impact of sleep on physical and mental well-being presents significant opportunities for market expansion. Patients are becoming more proactive in seeking treatment for chronic sleep disorders, while healthcare providers are emphasizing sleep management as part of overall wellness programs.

Pharmaceutical companies are also expanding into emerging markets through partnerships, licensing agreements, and commercialization initiatives to improve access to innovative insomnia therapies.

Market Challenges

Generic Competition and Patent Expirations

One of the key challenges facing the insomnia drugs market is the growing availability of generic alternatives. As patents expire, lower-cost generic versions gain market share, reducing revenue opportunities for branded manufacturers.

Price pressure from generic products is intensifying competition and forcing pharmaceutical companies to focus on innovation and product differentiation to maintain profitability.

Segment Analysis

By Drug Class

The Z-drugs/non-benzodiazepine hypnotics segment dominated the market in 2025 due to widespread physician familiarity and long-standing use in treating sleep onset and sleep maintenance difficulties. Drugs such as zolpidem and zopiclone continue to generate significant prescription volumes globally.

The Dual Orexin Receptor Antagonists (DORAs) segment is expected to be the fastest-growing category, registering a CAGR of 18.28% during the forecast period. Increasing acceptance of innovative therapies such as daridorexant and lemborexant is driving growth.

By Disease Indication

The primary chronic insomnia disorder segment held the largest market share in 2025. Chronic insomnia patients often require ongoing treatment, generating recurring demand for pharmaceutical therapies.

By Age Group

The adult segment dominated the market in 2025. Adults are more likely to experience insomnia due to stress, anxiety, work schedules, and age-related sleep disturbances. Most approved insomnia therapies are also specifically indicated for adult patients.

By Type

The generic drugs segment accounted for the largest share due to lower costs and broad accessibility. Generic versions of established insomnia medications remain widely prescribed in both developed and developing markets.

However, the branded segment is expected to grow at a CAGR of 10.05% through 2034, supported by the launch of innovative therapies.

By Route of Administration

The oral segment dominated the market because tablets and capsules offer convenience, ease of administration, and better patient compliance. Most leading insomnia drugs are available in oral formulations.

By Distribution Channel

The drug stores and retail pharmacies segment accounted for the largest market share in 2025. Since insomnia is primarily managed in outpatient settings, retail pharmacies remain the preferred dispensing channel for recurring prescriptions.

Regional Analysis

North America

North America led the global market with a valuation of USD 2.02 billion in 2025. Strong awareness regarding sleep disorders, favorable reimbursement policies, and rapid adoption of innovative insomnia therapies continue to support growth.

The U.S. insomnia drugs market is estimated at USD 2.01 billion in 2026, representing approximately 41.29% of global revenue.

Europe

Europe is projected to reach USD 1.31 billion in 2026, growing at a CAGR of 7.79%. Increased physician confidence in DORA therapies and broader reimbursement support are driving market expansion.

Germany and the U.K. remain among the largest regional markets.

Asia Pacific

Asia Pacific is expected to reach USD 1.01 billion in 2026, driven by increasing awareness of sleep health, rising healthcare spending, and growing adoption of branded insomnia medications.

China is projected to generate USD 0.35 billion in revenue in 2026, while Japan and India are estimated to reach USD 0.19 billion and USD 0.12 billion, respectively.

Latin America and Middle East & Africa

These regions are expected to experience moderate growth due to increasing diagnosis rates and improving access to modern insomnia therapies. Growing awareness and healthcare infrastructure development will continue to support market expansion.

Competitive Landscape

The insomnia drugs market is highly consolidated, with major pharmaceutical companies focusing on product innovation, strategic collaborations, licensing agreements, and geographical expansion.

Key companies operating in the market include:

• Eisai Co., Ltd.
• Idorsia Ltd
• Merck & Co., Inc.
• Takeda Pharmaceutical Company Limited
• Sanofi
• Pfizer Inc.
• Currax Pharmaceuticals LLC
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Lupin Limited

Recent industry developments include the continued global expansion of QUVIVIQ (daridorexant), strategic licensing partnerships, and the launch of advanced orexin receptor antagonist therapies across major markets.

Conclusion

The global insomnia drugs market is poised for sustained growth, expanding from USD 4.50 billion in 2025 to USD 8.90 billion by 2034. Rising prevalence of chronic insomnia, growing awareness of sleep health, increasing treatment-seeking behavior, and continuous innovation in orexin receptor antagonist therapies are expected to drive market expansion. Although challenges such as safety concerns and generic competition remain, the development of safer, more effective, and better-tolerated insomnia medications will continue to create substantial growth opportunities. As healthcare systems place greater emphasis on sleep health and overall well-being, the insomnia drugs market is expected to remain a vital segment of the global pharmaceutical industry throughout the forecast period.

Segmentation By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Region

By Drug Class * Dual Orexin Receptor Antagonists (DORAs)

• Z-drugs/Non-Benzodiazepine Hypnotics
• Benzodiazepine Hypnotics
• Melatonin Pathway Agents
• Others

By Disease Indication * Primary Chronic Insomnia Disorder

• Comorbid Psychiatric Insomnia
• Comorbid Neurologic/Pain-Related Insomnia
• Short-Term/Adjustment Insomnia
• Others

By Age Group * Adults

• Pediatrics

By Type * Branded

• Generic

By Route of Administration * Oral

• Others

By Distribution Channel * Hospital Pharmacies

• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Region * North America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country)

• U.S.
• Canada
• Europe (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Insomnia, By Key Countries /Regions, 2025
• 4.2. New Product Launches, By Key Players
• 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
• 4.4. Regulatory Scenario, By Key Countries/Regions

5. Global Insomnia Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Dual Orexin Receptor Antagonists (DORAs)
  • 5.1.2. Z-drugs/Non-Benzodiazepine Hypnotics
  • 5.1.3. Benzodiazepine Hypnotics
  • 5.1.4. Melatonin Pathway Agents
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.2.1. Primary Chronic Insomnia Disorder
  • 5.2.2. Comorbid Psychiatric Insomnia
  • 5.2.3. Comorbid Neurologic/Pain-Related Insomnia
  • 5.2.4. Short-Term/Adjustment Insomnia
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Age Group
  • 5.3.1. Adults
  • 5.3.2. Pediatrics
• 5.4. Market Analysis, Insights and Forecast - By Type
  • 5.4.1. Branded
  • 5.4.2. Generic
• 5.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.5.1. Oral
  • 5.5.2. Others
• 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.6.1. Hospital Pharmacies
  • 5.6.2. Drug Stores & Retail Pharmacies
  • 5.6.3. Online Pharmacies
• 5.7. Market Analysis, Insights and Forecast - Region
  • 5.7.1. North America
  • 5.7.2. Europe
  • 5.7.3. Asia Pacific
  • 5.7.4. Latin America
  • 5.7.5. Middle East & Africa

6. North America Insomnia Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Dual Orexin Receptor Antagonists (DORAs)
  • 6.1.2. Z-drugs/Non-Benzodiazepine Hypnotics
  • 6.1.3. Benzodiazepine Hypnotics
  • 6.1.4. Melatonin Pathway Agents
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.2.1. Primary Chronic Insomnia Disorder
  • 6.2.2. Comorbid Psychiatric Insomnia
  • 6.2.3. Comorbid Neurologic/Pain-Related Insomnia
  • 6.2.4. Short-Term/Adjustment Insomnia
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Age Group
  • 6.3.1. Adults
  • 6.3.2. Pediatrics
• 6.4. Market Analysis, Insights and Forecast - By Type
  • 6.4.1. Branded
  • 6.4.2. Generic
• 6.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.5.1. Oral
  • 6.5.2. Others
• 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.6.1. Hospital Pharmacies
  • 6.6.2. Drug Stores & Retail Pharmacies
  • 6.6.3. Online Pharmacies
• 6.7. Market Analysis, Insights and Forecast - By Country
  • 6.7.1. U.S.
  • 6.7.2. Canada

7. Europe Insomnia Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Dual Orexin Receptor Antagonists (DORAs)
  • 7.1.2. Z-drugs/Non-Benzodiazepine Hypnotics
  • 7.1.3. Benzodiazepine Hypnotics
  • 7.1.4. Melatonin Pathway Agents
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.2.1. Primary Chronic Insomnia Disorder
  • 7.2.2. Comorbid Psychiatric Insomnia
  • 7.2.3. Comorbid Neurologic/Pain-Related Insomnia
  • 7.2.4. Short-Term/Adjustment Insomnia
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Age Group
  • 7.3.1. Adults
  • 7.3.2. Pediatrics
• 7.4. Market Analysis, Insights and Forecast - By Type
  • 7.4.1. Branded
  • 7.4.2. Generic
• 7.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.5.1. Oral
  • 7.5.2. Others
• 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.6.1. Hospital Pharmacies
  • 7.6.2. Drug Stores & Retail Pharmacies
  • 7.6.3. Online Pharmacies
• 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.7.1. U.K.
  • 7.7.2. Germany
  • 7.7.3. France
  • 7.7.4. Italy
  • 7.7.5. Spain
  • 7.7.6. Scandinavia
  • 7.7.7. Rest of Europe

8. Asia Pacific Insomnia Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Dual Orexin Receptor Antagonists (DORAs)
  • 8.1.2. Z-drugs/Non-Benzodiazepine Hypnotics
  • 8.1.3. Benzodiazepine Hypnotics
  • 8.1.4. Melatonin Pathway Agents
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.2.1. Primary Chronic Insomnia Disorder
  • 8.2.2. Comorbid Psychiatric Insomnia
  • 8.2.3. Comorbid Neurologic/Pain-Related Insomnia
  • 8.2.4. Short-Term/Adjustment Insomnia
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Age Group
  • 8.3.1. Adults
  • 8.3.2. Pediatrics
• 8.4. Market Analysis, Insights and Forecast - By Type
  • 8.4.1. Branded
  • 8.4.2. Generic
• 8.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.5.1. Oral
  • 8.5.2. Others
• 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.6.1. Hospital Pharmacies
  • 8.6.2. Drug Stores & Retail Pharmacies
  • 8.6.3. Online Pharmacies
• 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.7.1. China
  • 8.7.2. Japan
  • 8.7.3. India
  • 8.7.4. Southeast Asia
  • 8.7.5. Australia
  • 8.7.6. Rest of Asia Pacific

9. Latin America Insomnia Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Dual Orexin Receptor Antagonists (DORAs)
  • 9.1.2. Z-drugs/Non-Benzodiazepine Hypnotics
  • 9.1.3. Benzodiazepine Hypnotics
  • 9.1.4. Melatonin Pathway Agents
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.2.1. Primary Chronic Insomnia Disorder
  • 9.2.2. Comorbid Psychiatric Insomnia
  • 9.2.3. Comorbid Neurologic/Pain-Related Insomnia
  • 9.2.4. Short-Term/Adjustment Insomnia
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Age Group
  • 9.3.1. Adults
  • 9.3.2. Pediatrics
• 9.4. Market Analysis, Insights and Forecast - By Type
  • 9.4.1. Branded
  • 9.4.2. Generic
• 9.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.5.1. Oral
  • 9.5.2. Others
• 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.6.1. Hospital Pharmacies
  • 9.6.2. Drug Stores & Retail Pharmacies
  • 9.6.3. Online Pharmacies
• 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.7.1. Brazil
  • 9.7.2. Mexico
  • 9.7.3. Rest of Latin America

10. Middle East & Africa Insomnia Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Dual Orexin Receptor Antagonists (DORAs)
  • 10.1.2. Z-drugs/Non-Benzodiazepine Hypnotics
  • 10.1.3. Benzodiazepine Hypnotics
  • 10.1.4. Melatonin Pathway Agents
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 10.2.1. Primary Chronic Insomnia Disorder
  • 10.2.2. Comorbid Psychiatric Insomnia
  • 10.2.3. Comorbid Neurologic/Pain-Related Insomnia
  • 10.2.4. Short-Term/Adjustment Insomnia
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By Age Group
  • 10.3.1. Adults
  • 10.3.2. Pediatrics
• 10.4. Market Analysis, Insights and Forecast - By Type
  • 10.4.1. Branded
  • 10.4.2. Generic
• 10.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.5.1. Oral
  • 10.5.2. Others
• 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.6.1. Hospital Pharmacies
  • 10.6.2. Drug Stores & Retail Pharmacies
  • 10.6.3. Online Pharmacies
• 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.7.1. GCC
  • 10.7.2. South Africa
  • 10.7.3. Rest of the Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Eisai Co., Ltd.
  • 11.2.2. Idorsia Ltd
  • 11.2.3. Merck & Co., Inc.
  • 11.2.4. Takeda Pharmaceutical Company Limited
  • 11.2.5. Sanofi
  • 11.2.6. Pfizer Inc.
  • 11.2.7. Currax Pharmaceuticals LLC
  • 11.2.8. Viatris Inc.
  • 11.2.9. Teva Pharmaceutical Industries Ltd.
  • 11.2.10. Lupin Limited